Immunofocusing using conformationally constrained V3 peptide immunogens improves HIV-1 neutralization (Q40415206)

20 September 2017

title

Immunofocusing using conformationally constrained V3 peptide immunogens improves HIV-1 neutralization (English)

1 reference

20 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939012 AND SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Adi Moseri

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939012 AND SRC:MED&resulttype=core&format=json

7 June 2020

Henni Zommer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939012 AND SRC:MED&resulttype=core&format=json

7 June 2020

Boris Arshava

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939012 AND SRC:MED&resulttype=core&format=json

7 June 2020

Fred Naider

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939012 AND SRC:MED&resulttype=core&format=json

7 June 2020

Jacob Anglister

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939012 AND SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

English

0 references

publication date

7 December 2016

1 reference

20 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939012 AND SRC:MED&resulttype=core&format=json

7 June 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939012 AND SRC:MED&resulttype=core&format=json

7 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939012 AND SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

222-230

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939012 AND SRC:MED&resulttype=core&format=json

Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Sieve analysis in HIV-1 vaccine efficacy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Antibodies Targeting the Envelope of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Structure of Antibody F425-B4e8 in Complex with a V3 Peptide Reveals a New Binding Mode for HIV-1 Neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

A cis proline turn linking two beta-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Cyclic V3-loop-related HIV-1 conjugate vaccines. Synthesis, conformation and immunological properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

A structure-based approach to a synthetic vaccine for HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2016.11.088

10.1016/J.VACCINE.2016.11.088

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939012 AND SRC:MED&resulttype=core&format=json

7 June 2020

1 reference